<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23127" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hyperbaric Oxygen Therapy for Intracranial Abscess</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Das</surname>
            <given-names>Joe M.</given-names>
          </name>
          <aff>Imperial College Healthcare NHS Trust, London</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tommeraasen</surname>
            <given-names>Miles A.</given-names>
          </name>
          <aff>University of Nebraska Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cooper</surname>
            <given-names>Jeffrey S.</given-names>
          </name>
          <aff>University of Nebraska Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Joe Das declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Miles Tommeraasen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jeffrey Cooper declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23127.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hyperbaric oxygen therapy (HBOT) involves administering 100% oxygen at pressures above 1.4 ATA and is being explored as an adjunctive treatment for intracranial abscesses, including cerebral abscesses and subdural and epidural empyema.&#x000a0;These abscesses develop during life-threatening infections, resulting in localized pus collections within the cranial cavity. Although the incidence is up to 1.3 per 100,000 individuals, intracranial abscesses occur more frequently in high-risk populations, such as patients with HIV/AIDS.</p>
        <p>Surgical aspiration or evacuation combined with antibiotics remains the standard treatment for intracranial abscesses. However, HBOT has shown promise as a valuable adjunct in certain cases. A retrospective cohort study found that patients receiving HBOT experienced lower morbidity, fewer reoperations, and a higher likelihood of returning to baseline function compared to those treated with standard therapy alone.&#x000a0;Treatment duration varies based on clinical response and imaging findings, with reports averaging 14 sessions. Although HBOT has antimicrobial benefits through reactive oxygen species, neurological sequelae remain a challenge, underscoring the need for effective adjunctive therapies.&#x000a0;This activity highlights the potential of HBOT in enhancing outcomes for patients with intracranial abscesses through effective collaboration among healthcare providers.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for hyperbaric oxygen therapy as an adjunctive treatment in patients with intracranial abscesses.</p></list-item><list-item><p>Implement evidence-based protocols for administering hyperbaric&#x000a0;oxygen&#x000a0;therapy, including appropriate pressure settings and session durations based on clinical guidelines.</p></list-item><list-item><p>Apply knowledge of the physiological mechanisms by which hyperbaric&#x000a0;oxygen&#x000a0;therapy enhances antibiotic efficacy and immune function in the context of intracranial infections.</p></list-item><list-item><p>Collaborate with the interprofessional healthcare team to develop individualized treatment plans incorporating hyperbaric oxygen therapy and&#x000a0;standard management strategies.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23127&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23127">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23127.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The first hyperbaric chamber was constructed in 1662 by Nathaniel Henshaw, a British clergyman. Over the years, various hyperbaric devices were used to treat different ailments, with varying degrees of success until 1955. Until then, the use of hyperbaric methods had minimal scientific support. The clinical application of hyperbaric oxygen therapy (HBOT) began in 1955 when Churchill-Davidson and colleagues explored its potential to enhance the effects of radiation therapy in cancer patients.<xref ref-type="bibr" rid="article-23127.r1">[1]</xref></p>
        <p>HBOT is a therapeutic modality that delivers 100% oxygen in a chamber or environment pressurized to more than 1.4 atmospheres absolute (ATA). The antimicrobial effects of HBOT are partly attributed to generating reactive oxygen species. HBOT is being explored as an adjunctive treatment for various conditions, including intracranial abscesses, with common examples being cerebral abscesses and subdural and epidural empyema. Please see StatPearls' companion resources, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/26805">Brain Abscess</ext-link>," "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/29622">Subdural Empyema</ext-link>," and "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/21222">Epidural Abscess</ext-link>," for more information about these clinical conditions.</p>
        <p>
<bold>Intracranial Abscess</bold>
</p>
        <p>An intracranial abscess is a localized, encapsulated collection of pus within the cranial cavity. While brain abscesses are relatively rare, occurring in only 0.3 to 1.3 per 100,000 individuals, their incidence is significantly higher among high-risk patients, particularly those with HIV infection or AIDS.<xref ref-type="bibr" rid="article-23127.r2">[2]</xref><xref ref-type="bibr" rid="article-23127.r3">[3]</xref><xref ref-type="bibr" rid="article-23127.r4">[4]</xref></p>
        <p><bold>Etiology and pathogenesis:&#x000a0;</bold>The development of an intracranial abscess involves several mechanisms, as mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Direct spread: This occurs when an initial infection spreads contiguously into adjacent tissues, such as the sinuses, ears, mastoid air cells, or teeth, affecting up to 60% of patients.</p>
          </list-item>
          <list-item>
            <p>Hematogenous seeding:&#x000a0;Infectious agents can reach the brain via the bloodstream, often leading to multiple abscesses.</p>
          </list-item>
          <list-item>
            <p>Cranial trauma:&#x000a0;Penetrating head injuries can provide a direct route for microorganisms to enter the skull.</p>
          </list-item>
        </list>
        <p><italic toggle="yes">Streptococcus</italic> and <italic toggle="yes">Staphylococcus</italic> species&#x000a0;are&#x000a0;the most common bacterial causes of brain abscesses, with viridans group streptococci (VGS) and&#x000a0;<italic toggle="yes">Staphylococcus aureus</italic> being the most prevalent. Anaerobes are also commonly found in brain abscesses, originating from the normal oral flora. When determining the cause of an infection, it is essential to consider the patient's immune status. Bacterial abscesses are typically observed in immunocompetent individuals, whereas immunocompromised patients may be infected by various organisms, including fungi.<xref ref-type="bibr" rid="article-23127.r5">[5]</xref></p>
        <p>
<bold>Factors Contributing to Improved Outcomes</bold>
</p>
        <p>Although brain abscesses are a rare condition, mortality rates remain high among affected patients. However, the prognosis for these individuals has significantly improved compared to historical data. A systematic review and meta-analysis revealed that over the past 6 decades, the case fatality rate has decreased from 40% to 10%, while the proportion of patients achieving full recovery has increased from 33% to 70%.<xref ref-type="bibr" rid="article-23127.r6">[6]</xref>&#x000a0;Additionally, a study of 289 patients with pyogenic brain abscesses treated between 1999 and 2006 reported a mortality rate as low as 2.7%.<xref ref-type="bibr" rid="article-23127.r7">[7]</xref></p>
        <p>Several factors, as mentioned below, have contributed to this positive trend.</p>
        <list list-type="bullet">
          <list-item>
            <p>Computed tomography:&#x000a0;The advent of computed tomography (CT) imaging has significantly improved outcomes by enabling faster diagnoses and facilitating less invasive, more precise neurosurgical interventions, such as stereotactic aspiration. One retrospective study showed a reduction in mortality from 40% to 20% within the first decade following the introduction of CT.</p>
          </list-item>
          <list-item>
            <p>Neurosurgical techniques: Advancements in neurosurgical procedures and the precision offered by CT-guided interventions have improved abscess drainage and reduced complications.</p>
          </list-item>
          <list-item>
            <p>Antimicrobial therapy:&#x000a0;The development of more effective antibiotics has been crucial for controlling infections.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23127.s3" sec-type="Anatomy and Physiology">
        <title>Anatomy and Physiology</title>
        <p>
<bold>Principles Governing Oxygen Delivery in&#x000a0;Hyperbaric Oxygen Therapy</bold>
</p>
        <p>The theoretical framework and clinical effectiveness of HBOT are based on the principles of increased oxygen delivery, which is governed by the physical laws below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Dalton's law: This law of partial pressures states that the total pressure of a gas mixture equals the sum of the partial pressures of each component&#x000a0;gas. Dalton's law explains how variations in pressure or gas concentration influence the partial pressure of a specific gas within the mixture.</p>
          </list-item>
          <list-item>
            <p>Henry's law: According to this law, the concentration of a gas dissolved in a liquid is directly proportional to its partial pressure and solubility. This&#x000a0;law underlies the increased oxygen levels dissolved in blood during HBOT.</p>
          </list-item>
        </list>
        <p>
<bold>Oxygen Delivery During <bold>Hyperbaric Oxygen Therapy</bold></bold>
</p>
        <p>The effectiveness of HBOT in enhancing oxygen delivery to tissues relies on several fundamental principles of gas transport and diffusion, as mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Normal conditions:&#x000a0;Under typical conditions, hemoglobin carries the majority of oxygen, with only a small amount (3 mL/L) dissolved in plasma.</p>
          </list-item>
          <list-item>
            <p>100% oxygen:&#x000a0;When breathing 100% oxygen, the dissolved oxygen level increases to 15 mL/L.</p>
          </list-item>
          <list-item>
            <p>HBOT at 2.5 ATA: Dissolves 60 mL/L of oxygen to support resting tissue metabolism without relying on hemoglobin-bound oxygen.</p>
          </list-item>
          <list-item>
            <p>Diffusion: Oxygen reaches cells through diffusion, which is influenced by the distance from capillaries and local oxygen levels.</p>
          </list-item>
          <list-item>
            <p>HBOT and diffusion: The increased PO<sub>2</sub> at the capillary extends the diffusion distance 3-fold.</p>
          </list-item>
        </list>
        <p>
<bold>Proposed Mechanisms of Action for Hyperbaric Oxygen Therapy in Treating Intracranial Abscesses</bold>
</p>
        <p>HBOT is being explored as an adjunctive treatment for intracranial abscesses, with several proposed mechanisms of action, as mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Reduction of perifocal brain swelling: HBOT can&#x000a0;cause vasoconstriction and decreased cerebral blood flow, which may help reduce edema and intracranial pressure associated with brain abscesses.</p>
          </list-item>
          <list-item>
            <p>Inhibition of anaerobic organisms: Many intracranial abscesses involve anaerobic bacteria. The high-oxygen environment created by HBOT is detrimental to the growth and survival of these organisms.</p>
          </list-item>
          <list-item>
            <p>Enhancement of neutrophil function: HBOT has been shown to increase the oxygen-dependent killing mechanisms of neutrophils,&#x000a0;which are the key immune cell subtypes involved in fighting infection. This enhanced phagocytosis may aid in clearing the infecting organisms.</p>
          </list-item>
          <list-item>
            <p>Treatment of concomitant skull osteomyelitis: In cases where the infection has spread to the skull bone, HBOT can facilitate treatment by increasing oxygen delivery to the affected area and promoting healing.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23127.s4" sec-type="Indications">
        <title>Indications</title>
        <p>According to the Undersea and Hyperbaric Medical Society (UHMS), adjunct&#x000a0;HBOT should be considered for the treatment of intracranial abscesses in the following situations:</p>
        <list list-type="bullet">
          <list-item>
            <p>Compromised host</p>
          </list-item>
          <list-item>
            <p>Multiple abscesses</p>
          </list-item>
          <list-item>
            <p>Abscesses in a deep or dominant location</p>
          </list-item>
          <list-item>
            <p>Patients&#x000a0;for whom surgery is contraindicated</p>
          </list-item>
          <list-item>
            <p>Patients who are poor surgical candidates</p>
          </list-item>
          <list-item>
            <p>Patients who deteriorate or show no response to standard surgical and antibiotic therapies</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23127.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Absolute Contraindications</bold>
</p>
        <p><bold>Untreated pneumothorax:</bold>&#x000a0;This is the only absolute contraindication to HBOT. A pneumothorax occurs when air becomes trapped in the pleural space, and the increased pressure during HBOT can cause it to expand dangerously, leading to tension pneumothorax and potentially life-threatening complications.</p>
        <p>
<bold>Relative Contraindications</bold>
</p>
        <p><bold>Claustrophobia:</bold>&#x000a0;The enclosed environment of the hyperbaric chamber can trigger anxiety or panic attacks in individuals with claustrophobia.</p>
        <p><bold>Obstructive lung disease:</bold>&#x000a0;Conditions such as chronic obstructive pulmonary disease can impair gas exchange and increase the risk of complications during HBOT.</p>
        <p><bold>Asymptomatic pulmonary blebs:&#x000a0;</bold>These small air pockets in the lungs can rupture under increased pressure, potentially leading to pneumothorax.</p>
        <p><bold>Upper respiratory or sinus infections:</bold>&#x000a0;Pressure changes during HBOT can worsen symptoms or cause ear and sinus barotrauma.</p>
        <p><bold>Recent ear or thoracic surgery:</bold>&#x000a0;Healing tissues may be more susceptible to pressure changes and barotrauma.</p>
        <p><bold>Uncontrolled seizures:&#x000a0;</bold>HBOT may potentially lower the seizure threshold in some individuals.</p>
        <p>Relative contraindications do not automatically exclude the use of HBOT. Each patient should be evaluated individually, weighing the potential benefits against the risks in consultation with a qualified healthcare professional. In some cases, appropriate management or modifications may enable patients with relative contraindications to safely undergo HBOT.</p>
      </sec>
      <sec id="article-23127.s6" sec-type="Equipment">
        <title>Equipment</title>
        <p>HBOT is administered in a chamber where the patient is placed. There are 2 types of chambers, as mentioned below.<xref ref-type="bibr" rid="article-23127.r8">[8]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Monoplace chamber:&#x000a0;The&#x000a0;patient&#x000a0;inhales pressurized 100% oxygen directly in this chamber.</p>
          </list-item>
          <list-item>
            <p>Multiplace chamber:&#x000a0;Multiple&#x000a0;patients inhale pressurized 100% oxygen&#x000a0;indirectly through a head hood, mask, or endotracheal tube in this setup.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23127.s7" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p>
<bold>Recommended Protocol</bold>
</p>
        <p>The UHMS offers guidelines for administering HBOT in cases of intracranial abscesses, which are mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Pressure: The recommended pressure ranges from 2.0 to 2.5 ATA.</p>
          </list-item>
          <list-item>
            <p>Oxygen administration duration: Each treatment session lasts 60 to 90 minutes.</p>
          </list-item>
          <list-item>
            <p>Frequency: Depending on the patient's clinical condition, treatments may be administered once or twice daily.</p>
          </list-item>
        </list>
        <p>
<bold>Duration of Therapy</bold>
</p>
        <p>Although definitive guidelines for the optimal number of HBOT sessions for intracranial abscesses do not exist, the largest case series reported an average of 14 sessions in patients without osteomyelitis. The duration of therapy should be individualized based on the below-mentioned criteria.<xref ref-type="bibr" rid="article-23127.r9">[9]</xref><xref ref-type="bibr" rid="article-23127.r10">[10]</xref><xref ref-type="bibr" rid="article-23127.r11">[11]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Radiological findings: Serial imaging studies (eg, CT or magnetic resonance imaging [MRI] scans) can be used to monitor the size and resolution of the abscess.</p>
          </list-item>
          <list-item>
            <p>Clinical response: Improvement in neurological symptoms and signs can help guide treatment decisions.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23127.s8" sec-type="Complications">
        <title>Complications</title>
        <p>
<bold>Barotrauma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Middle ear barotrauma: This&#x000a0;is the most frequent complication, particularly in patients undergoing multiple treatments. This arises due to pressure differences between the middle ear and the hyperbaric chamber. Symptoms may include ear pain, tympanic membrane rupture, and even hearing loss.</p>
          </list-item>
          <list-item>
            <p>Sinus barotrauma: This is the second most common complication, often affecting individuals with preexisting conditions such as upper respiratory infections or allergic rhinitis. This complication typically manifests as sinus pain and congestion.</p>
          </list-item>
        </list>
        <p>
<bold>Pulmonary Complications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pulmonary oxygen toxicity: This condition may develop with multiple treatments, causing chest tightness due to lung irritation from extended exposure to high oxygen concentrations.</p>
          </list-item>
          <list-item>
            <p>Pulmonary barotrauma: This is a rare but severe complication caused by pressure changes that damage lung tissue, potentially leading to pneumothorax or pneumomediastinum.<xref ref-type="bibr" rid="article-23127.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Central Nervous System Oxygen Toxicity</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Seizures:&#x000a0;Seizures are a rare but serious&#x000a0;complication, with an incidence of only one seizure reported per 62,614 hyperbaric sessions involving 2334 patients. The risk increases with prolonged exposure (over 90&#x02013;120 min) or when pressures exceed 2.8 ATA.</p>
          </list-item>
          <list-item>
            <p>Management: If a seizure occurs, the oxygen concentration should be immediately reduced, and anticonvulsant medications may be administered as needed.<xref ref-type="bibr" rid="article-23127.r13">[13]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23127.s9" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>Limitations of Conventional Therapy and Need for Adjunctive Treatment</bold>
</p>
        <p>Despite advancements in reducing mortality rates, significant challenges persist in managing intracranial abscesses. Neurologic sequelae are common, with some being severe enough to impact patients' social and professional lives. This underscores the urgent need for more effective and conservative treatment strategies.</p>
        <p>Antibiotic treatment for intracranial abscesses has various limitations, as mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Limited penetration: Antibiotics may not readily cross the blood-brain barrier, ischemic tissues, or the abscess capsule.</p>
          </list-item>
          <list-item>
            <p>Hypoxic and acidic environment: The local environment within an abscess can significantly reduce the effectiveness of antibiotics.</p>
          </list-item>
          <list-item>
            <p>Impaired immune function: Hypoxia within the abscess can impair white blood cell phagocytic function, thereby&#x000a0;diminishing the antimicrobial effects of antibiotics.</p>
          </list-item>
        </list>
        <p>
<bold>Potential Benefits of <bold>Hyperbaric Oxygen Therapy</bold></bold>
</p>
        <p>HBOT helps overcome the limitations of conventional treatment through several physiological mechanisms, as listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Correction of tissue hypoxia: Increased oxygen delivery improves tissue oxygenation, alleviating the hypoxic environment within the abscess.</p>
          </list-item>
          <list-item>
            <p>Direct antimicrobial effects: HBOT exerts bacteriostatic and bactericidal effects, particularly against anaerobic organisms.</p>
          </list-item>
          <list-item>
            <p>Enhanced antibiotic efficacy: Improved tissue oxygenation can enhance antibiotic penetration and effectiveness within infected tissues.</p>
          </list-item>
          <list-item>
            <p>Enhanced immune function: HBOT can improve neutrophil-mediated phagocytosis, thereby strengthening the immune response against infections.</p>
          </list-item>
          <list-item>
            <p>Reduced brain swelling: The vasoconstrictive and dose-dependent anti-inflammatory effects of HBOT can help reduce edema and intracranial pressure.</p>
          </list-item>
        </list>
        <p>
<bold>Evidence for Hyperbaric Oxygen Therapy Efficacy</bold>
</p>
        <p>Although data remain limited, a recent retrospective cohort study showed promising results with adjuvant HBOT in treating&#x000a0;intracranial abscesses. Patients receiving HBOT showed lower morbidity, decreased reoperation rates, and a higher likelihood of returning to their premorbid functional state compared to those receiving standard therapy alone.<xref ref-type="bibr" rid="article-23127.r3">[3]</xref></p>
        <p>HBOT offers potentially valuable adjunctive therapy for intracranial abscesses, overcoming the limitations of conventional treatment and offering additional benefits. Although further research is required, the available limited evidence supports its use in specific clinical scenarios.</p>
      </sec>
      <sec id="article-23127.s10" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The primary treatment for intracranial abscesses usually involves a combination of the below-mentioned criteria.</p>
        <list list-type="bullet">
          <list-item>
            <p>Antibiotics: Targeted antibiotic therapy is crucial for controlling the infection. The choice of antibiotics depends on the suspected or identified causative organisms.</p>
          </list-item>
          <list-item>
            <p>Drainage: Surgical drainage or aspiration of the abscess is often necessary to remove the purulent material and reduce intracranial pressure. Various techniques can be used, including stereotactic aspiration, open craniotomy, or endoscopic drainage.</p>
          </list-item>
        </list>
        <p>HBOT is being explored as an adjunctive therapy for intracranial abscesses, and key considerations are mentioned below.<xref ref-type="bibr" rid="article-23127.r14">[14]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>First-line treatment: HBOT is not intended as the primary therapy but should be used alongside standard antibiotic and surgical management.</p>
          </list-item>
          <list-item>
            <p>Unstable patients: HBOT is generally not recommended for individuals with unstable vital signs or those in need of urgent surgical intervention.</p>
          </list-item>
          <list-item>
            <p>Replacement for antibiotics: HBOT serves as a complementary therapy (adjunct) to enhance antibiotic effectiveness, not as a substitute for antibiotic treatment.</p>
          </list-item>
          <list-item>
            <p>Potential risks: HBOT&#x000a0;carries risks such as barotrauma and oxygen toxicity, which require careful monitoring and management.</p>
          </list-item>
        </list>
        <p>However, HBOT shows significant potential as an adjunctive therapy, supported by its physiological benefits and evidence from case reports and series.<xref ref-type="bibr" rid="article-23127.r15">[15]</xref><xref ref-type="bibr" rid="article-23127.r16">[16]</xref></p>
      </sec>
      <sec id="article-23127.s11" sec-type="Nursing, Allied Health, and Interprofessional Team Monitoring">
        <title>Nursing, Allied Health, and Interprofessional Team Monitoring</title>
        <p>The management of intracranial abscesses necessitates a collaborative approach involving an interprofessional healthcare team, which includes neurosurgeons, infectious disease specialists, neurologists, neurocritical care nurses, radiologists, pharmacists, and rehabilitation specialists.</p>
      </sec>
      <sec id="article-23127.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23127&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23127">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23127/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23127">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23127.s13">
        <title>References</title>
        <ref id="article-23127.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaide</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Khandelwal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Hyperbaric oxygen: applications in infectious disease.</article-title>
            <source>Emerg Med Clin North Am</source>
            <year>2008</year>
            <month>May</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>571</fpage>
            <page-range>571-95, xi</page-range>
            <pub-id pub-id-type="pmid">18406988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23127.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bosco</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Garetto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rubini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dalvi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mangar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Camporesi</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Safety of transport and hyperbaric oxygen treatment in critically-ill patients from Padua hospitals into a centrally-located, stand-alone hyperbaric facility.</article-title>
            <source>Diving Hyperb Med</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>46</volume>
            <issue>3</issue>
            <fpage>155</fpage>
            <page-range>155-159</page-range>
            <pub-id pub-id-type="pmid">27723016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23127.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bartek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jakola</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Skyrman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>F&#x000f6;rander</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alpkvist</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schechtmann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Glim&#x000e5;ker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Larsson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lind</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mathiesen</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Hyperbaric oxygen therapy in spontaneous brain abscess patients: a population-based comparative cohort study.</article-title>
            <source>Acta Neurochir (Wien)</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>158</volume>
            <issue>7</issue>
            <fpage>1259</fpage>
            <page-range>1259-67</page-range>
            <pub-id pub-id-type="pmid">27113742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23127.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnes</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Intracranial abscess.</article-title>
            <source>Undersea Hyperb Med</source>
            <year>2012</year>
            <season>May-Jun</season>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>727</fpage>
            <page-range>727-30</page-range>
            <pub-id pub-id-type="pmid">22670553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23127.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lampl</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[Hyperbaric oxygenation: utility in intensive therapy - part 2].</article-title>
            <source>Anasthesiol Intensivmed Notfallmed Schmerzther</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>44</volume>
            <issue>10</issue>
            <fpage>652</fpage>
            <page-range>652-8</page-range>
            <pub-id pub-id-type="pmid">19834829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23127.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brouwer</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Coutinho</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>van de Beek</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Clinical characteristics and outcome of brain abscess: systematic review and meta-analysis.</article-title>
            <source>Neurology</source>
            <year>2014</year>
            <month>Mar</month>
            <day>04</day>
            <volume>82</volume>
            <issue>9</issue>
            <fpage>806</fpage>
            <page-range>806-13</page-range>
            <pub-id pub-id-type="pmid">24477107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23127.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muzumdar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jhawar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goel</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Brain abscess: an overview.</article-title>
            <source>Int J Surg</source>
            <year>2011</year>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>136</fpage>
            <page-range>136-44</page-range>
            <pub-id pub-id-type="pmid">21087684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23127.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Memar</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Yekani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alizadeh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Baghi</surname>
                <given-names>HB</given-names>
              </name>
            </person-group>
            <article-title>Hyperbaric oxygen therapy: Antimicrobial mechanisms and clinical application for infections.</article-title>
            <source>Biomed Pharmacother</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>109</volume>
            <fpage>440</fpage>
            <page-range>440-447</page-range>
            <pub-id pub-id-type="pmid">30399579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23127.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacFarlane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cronj&#x000e9;</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Hyperbaric oxygen and surgery.</article-title>
            <source>S Afr J Surg</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>117</fpage>
            <page-range>117-21</page-range>
            <pub-id pub-id-type="pmid">11820141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23127.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gamba</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Woodruff</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Djang</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Yeates</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Craniofacial mucormycosis: assessment with CT.</article-title>
            <source>Radiology</source>
            <year>1986</year>
            <month>Jul</month>
            <volume>160</volume>
            <issue>1</issue>
            <fpage>207</fpage>
            <page-range>207-12</page-range>
            <pub-id pub-id-type="pmid">3715034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23127.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000f6;tze</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bloching</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hainz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knipping</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[Invasive aspergillosis of the skull base with orbit infiltration].</article-title>
            <source>HNO</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>55</volume>
            <issue>7</issue>
            <fpage>560</fpage>
            <page-range>560-3</page-range>
            <pub-id pub-id-type="pmid">16625369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23127.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Camporesi</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Side effects of hyperbaric oxygen therapy.</article-title>
            <source>Undersea Hyperb Med</source>
            <year>2014</year>
            <season>May-Jun</season>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>253</fpage>
            <page-range>253-7</page-range>
            <pub-id pub-id-type="pmid">24984321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23127.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ciarlone</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Hinojo</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Stavitzski</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>CNS function and dysfunction during exposure to hyperbaric oxygen in operational and clinical settings.</article-title>
            <source>Redox Biol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>27</volume>
            <fpage>101159</fpage>
            <pub-id pub-id-type="pmid">30902504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23127.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Cha</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Operation of a hyperbaric oxygen therapy center in Korea: Report of our experience from a setting in its nascent stages.</article-title>
            <source>Undersea Hyperb Med</source>
            <string-date>2019 Mar-Apr-May</string-date>
            <volume>46</volume>
            <issue>2</issue>
            <fpage>135</fpage>
            <page-range>135-143</page-range>
            <pub-id pub-id-type="pmid">31051058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23127.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kjellberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bjerin</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Franz&#x000e9;n-R&#x000f6;hl</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bartek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lindholm</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Lemierre's syndrome caused by <italic>Fusobacterium necrophorum</italic> complicated with multiple brain abscesses-A case report, literature review, and suggested management.</article-title>
            <source>Clin Case Rep</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>9</volume>
            <issue>12</issue>
            <fpage>e05142</fpage>
            <pub-id pub-id-type="pmid">34917365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23127.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomoye</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Hyperbaric oxygen for intracranial abscess.</article-title>
            <source>Undersea Hyperb Med</source>
            <year>2021</year>
            <season>First Quarter</season>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>97</fpage>
            <page-range>97-102</page-range>
            <pub-id pub-id-type="pmid">33648039</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
